LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia

• Status: Completed
• Trial end date: 2014-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study objective is to improve the global results obtained with LAL-AR-93 study, reaching an event free survival between 60-70%.

Identify patients with bad prognosis, with minimal residual disease,who can benefit of allogenic bone marrow transplantation

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PETHEMA Foundation
• Treatments: Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Methotrexate; Prednisolone; Vincristine

Criteria

Inclusion Criteria:

• High risk children with acute lymphoblastic leukemia

Exclusion Criteria:

• Mature B-ALL (FABL3)

• Mixed forms of ALL

• Patients with coronary disorders, valvular or hypertensive cardiopathy

• Patients with chronic liver disorders

• Chronic pulmonary disorders

• Renal insufficiency

• Neurologic disfunctions

• ECOG 3 and 4